金河生物上半年净利大幅增长，董事长王东晓年过七旬

Group 1 - The core viewpoint of the news is that Jinhe Biology (002688.SZ) reported significant growth in its financial performance for the first half of 2025, with a notable increase in both revenue and net profit [1] - In the first half of 2025, the company's operating revenue reached 1.39 billion yuan, representing a year-on-year growth of 30.45%, while the net profit attributable to shareholders was 138 million yuan, up 51.52% [1] - The growth in performance is attributed to the company's focus on its core animal health business, which has established a dual-driven model of veterinary pharmaceuticals and vaccines, supported by environmental protection and agricultural product processing [1] Group 2 - In 2024, Jinhe Biology reported an operating revenue of 2.37 billion yuan, reflecting a year-on-year increase of 9.04%, and a net profit attributable to shareholders of 100 million yuan, which is a 15.90% growth [3] - The chairman of Jinhe Biology, Wang Dongxiao, is 73 years old and holds a graduate degree, also serving in various leadership roles in related companies [3] - Wang Dongxiao's compensation from 2020 to 2024 has shown slight fluctuations, with amounts of 943,200 yuan, 945,100 yuan, 844,800 yuan, 880,500 yuan, and 873,000 yuan respectively [3]